Your browser doesn't support javascript.
loading
An overview of the latest outlook of sulfamate derivatives as anticancer candidates (2020-2024).
Mustafa, Esra M; Shahin, Afnan I; Alrashed, Aishah S; Bahaaddin, Aesheh H; Alajmi, Aljawhra A; Hashem, Omar; Anbar, Hanan S; El-Gamal, Mohammed I.
Affiliation
  • Mustafa EM; Research, Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
  • Shahin AI; Research, Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
  • Alrashed AS; College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
  • Bahaaddin AH; College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
  • Alajmi AA; College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
  • Hashem O; Research, Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
  • Anbar HS; Department of Pharmaceutical Sciences, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates.
  • El-Gamal MI; Research, Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Arch Pharm (Weinheim) ; 357(10): e2400331, 2024 Oct.
Article in En | MEDLINE | ID: mdl-38943437
ABSTRACT
Considering the emergence of new anticancer drugs, in this review we emphasized and highlighted the recent reports and advances related to sulfamate-incorporating compounds with potential anticancer activity during the last 5 years (2020-2024). Additionally, we discussed their structure-activity relationship, clarifying their potent bioactivity as anticancer agents. Sulfamate derivatives hold promise as effective therapeutic candidates against cancer. By targeting biological targets associated with the development of cancer, such as steroid sulfatases (STS), carbonic anhydrases (CAs), microtubules, NEDD8-activating enzyme, small ubiquitin-like modifiers (SUMO)-activating enzyme (SAE), cyclin-dependent kinases (CDKs), breast cancer susceptibility gene 1 (BRCA1), and so on, this can furnish small molecules as anticancer lead candidates serving the drug discovery field. For example, compound 2, an STS inhibitor, demonstrated superior activity compared to its reference, irosustat, by fivefold. In addition, compound 21, an SAE, is under phase I clinical trials. Continued research into sulfamate derivatives holds potential for the development of novel therapeutic agents targeting various diseases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonic Acids / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Arch Pharm (Weinheim) Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonic Acids / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Arch Pharm (Weinheim) Year: 2024 Document type: Article Affiliation country: Country of publication: